Curis stock has recently drawn increased attention following the latest round of analyst updates, with the consensus price target holding steady at $14.00 per share. While forecasts show little ...

Curis, Inc. (NASDAQ:CRIS) defied analyst predictions to release its quarterly results, which were ahead of market expectations. Revenues of US$3.2m were better than expected, some 11% ahead of ...

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

The FDA has freed Curis from a remaining partial clinical hold, lifting the pause on a phase 1/2 leukemia study and giving the green light to launch using the recommended phase 2 dose. In April 2022, ...

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients ...